These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 11713766

  • 41. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW, Li D, McQuone SJ, Ralston R.
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [Abstract] [Full Text] [Related]

  • 42. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
    Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK.
    Cancer Gene Ther; 2006 Aug; 13(8):806-14. PubMed ID: 16628227
    [Abstract] [Full Text] [Related]

  • 43. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
    Oakley R, Phillips E, Hooper R, Wilson D, Partridge M.
    Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
    [Abstract] [Full Text] [Related]

  • 44. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.
    Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, Malkin D.
    Cancer Gene Ther; 2006 Apr; 13(4):415-9. PubMed ID: 16211088
    [Abstract] [Full Text] [Related]

  • 45. [A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer].
    Fujiwara T, Kataoka M, Kawamata O, Tanaka N.
    Nihon Geka Gakkai Zasshi; 1999 Nov; 100(11):749-55. PubMed ID: 10629843
    [Abstract] [Full Text] [Related]

  • 46. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
    Atencio IA, Avanzini JB, Johnson D, Neuteboom S, Vaillancourt MT, Nielsen LL, Hajian G, Sutjipto S, Sugarman BJ, Philopena J, McAllister DL, Beltran JC, Nodelman M, Ramachandra M, Wills KN.
    Mol Ther; 2001 Jul; 4(1):5-12. PubMed ID: 11472100
    [Abstract] [Full Text] [Related]

  • 47. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
    Lipinski KS, Djeha AH, Krausz E, Lane DP, Searle PF, Mountain A, Wrighton CJ.
    Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
    [Abstract] [Full Text] [Related]

  • 48. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model.
    Turturro F, Heineke HL, Drevyanko TF, Link CJ, Seth P.
    Gene Ther; 2000 Jun; 7(11):930-3. PubMed ID: 10849552
    [Abstract] [Full Text] [Related]

  • 49. Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumors.
    Okimoto T, Yahata H, Itou H, Shinozaki K, Tanji H, Sakaguchi T, Asahara T.
    J Exp Clin Cancer Res; 2003 Sep; 22(3):399-406. PubMed ID: 14582698
    [Abstract] [Full Text] [Related]

  • 50. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma.
    Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ.
    Cancer Res; 1995 Jan 01; 55(1):1-6. PubMed ID: 7805018
    [Abstract] [Full Text] [Related]

  • 51. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer.
    Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S.
    Anticancer Res; 1998 Jan 01; 18(4C):3087-92. PubMed ID: 9713515
    [Abstract] [Full Text] [Related]

  • 52. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
    Kühnel F, Zender L, Wirth T, Schulte B, Trautwein C, Manns M, Kubicka S.
    Cancer Gene Ther; 2004 Jan 01; 11(1):28-40. PubMed ID: 14681724
    [Abstract] [Full Text] [Related]

  • 53. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA.
    Cancer Res; 1994 May 01; 54(9):2287-91. PubMed ID: 8162565
    [Abstract] [Full Text] [Related]

  • 54. Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials.
    Overholt SM, Liu TJ, Taylor DL, Wang M, El-Naggar AK, Shillitoe E, Adler-Storthz K, John LS, Zhang WW, Roth JA, Clayman GL.
    Clin Cancer Res; 1997 Feb 01; 3(2):185-91. PubMed ID: 9815671
    [Abstract] [Full Text] [Related]

  • 55. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.
    Wen SF, Mahavni V, Quijano E, Shinoda J, Grace M, Musco-Hobkinson ML, Yang TY, Chen Y, Runnenbaum I, Horowitz J, Maneval D, Hutchins B, Buller R.
    Cancer Gene Ther; 2003 Mar 01; 10(3):224-38. PubMed ID: 12637944
    [Abstract] [Full Text] [Related]

  • 56. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation.
    Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA.
    Clin Cancer Res; 1996 Oct 01; 2(10):1665-71. PubMed ID: 9816114
    [Abstract] [Full Text] [Related]

  • 57. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
    Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-Müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Müller MR, Roth E, Klepetko W.
    J Thorac Cardiovasc Surg; 2008 May 01; 135(5):1036-41. PubMed ID: 18455581
    [Abstract] [Full Text] [Related]

  • 58. p53 gene status and chemosensitivity in ovarian cancer.
    Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N.
    Hum Cell; 2001 Sep 01; 14(3):165-71. PubMed ID: 11774736
    [Abstract] [Full Text] [Related]

  • 59. Current status of gene therapy for lung cancer and head and neck cancer.
    Moon C, Oh Y, Roth JA.
    Clin Cancer Res; 2003 Nov 01; 9(14):5055-67. PubMed ID: 14613982
    [Abstract] [Full Text] [Related]

  • 60. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus.
    Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL.
    Cancer Res; 1994 Jul 15; 54(14):3662-7. PubMed ID: 8033080
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.